Kamada Ltd. (KMDA) Strengthens Leadership Team With The Addition Of Vice President-Medical Director

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the Company has strengthened its senior leadership team with the appointment of Eran Schenker, M.D. to the newly created position of Vice President-Medical Director Dr. Schenker will report to David Tsur, co-founder and CEO of Kamada.

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.